Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500849 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
A Phase 1 study of HIV, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 5
- Study locations
NCT02500849 is a Phase 1 study of HIV that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 12 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT02500849, a Phase 1 study of HIV, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.
Conditions Studied
Interventions
- GENETIC SB-728mR-HSPC Infusion 3 days following busulfan conditioning
Study Locations (5)
California
- City of Hope Medical Center - Duarte
- UCLA CARE Center - Los Angeles
- Mills Clinical Research - Los Angeles
- Quest Clinical Research - San Francisco
Connecticut
- Circle CARE Center, LLC - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-03-10 |
| Est. Completion | 2026-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02500849
The ClinicalTrials.gov registry entry for NCT02500849 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (97% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which SB-728mR-HSPC Infusion 3 days following busulfan conditioning is the first listed.
NCT02500849 reports 5 study locations spanning 2 distinct geographic areas - top geographies include California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02500849 about?
NCT02500849 is a clinical study titled "Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients". The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.
What is the current status of trial NCT02500849?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-03-10. Estimated completion is 2026-08-24.
What conditions does trial NCT02500849 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT02500849?
The interventions under investigation include: SB-728mR-HSPC Infusion 3 days following busulfan conditioning (GENETIC).
Who is sponsoring clinical trial NCT02500849?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02500849 being conducted?
This trial has 5 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
RECRUITING · Phase 1
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
-
A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV
ACTIVE NOT RECRUITING · Phase 1
-
Oral Dronabinol-HIV
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.